SG11201708692WA - Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof - Google Patents
Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereofInfo
- Publication number
- SG11201708692WA SG11201708692WA SG11201708692WA SG11201708692WA SG11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA
- Authority
- SG
- Singapore
- Prior art keywords
- thiadiazolidine
- dioxide
- preparation
- salt form
- crystal form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B41/00—Formation or introduction of functional groups containing oxygen
- C07B41/02—Formation or introduction of functional groups containing oxygen of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510703726 | 2015-10-26 | ||
PCT/CN2016/103297 WO2017071569A1 (zh) | 2015-10-26 | 2016-10-25 | 1, 2, 5-噻二唑烷-1, 1-二氧化物的盐型、晶型及其制备方法和中间体 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708692WA true SG11201708692WA (en) | 2017-11-29 |
Family
ID=58629863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708692WA SG11201708692WA (en) | 2015-10-26 | 2016-10-25 | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US10227339B2 (es) |
EP (1) | EP3257851B1 (es) |
JP (1) | JP6427695B2 (es) |
KR (1) | KR102048391B1 (es) |
CN (1) | CN107406439B (es) |
DK (1) | DK3257851T3 (es) |
ES (1) | ES2835061T3 (es) |
MY (1) | MY174415A (es) |
SG (1) | SG11201708692WA (es) |
WO (1) | WO2017071569A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113940918B (zh) * | 2020-07-17 | 2023-06-02 | 江苏康缘药业股份有限公司 | 一种药物组合物及制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2658906A1 (de) * | 1976-12-24 | 1978-07-06 | Bayer Ag | Beta-lactam-antibiotika, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
ZA846525B (en) * | 1983-08-29 | 1985-04-24 | Sterling Drug Inc | (substituted)phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof |
US5750546A (en) * | 1994-12-02 | 1998-05-12 | Sanofi Winthrop, Inc. | 2-(2, 3, 5, 6-tetrafluoro-4-pyridyl)-1, 2, 5-thiadiazolidin-3-one 1, 1-dioxides and compositions and method of use thereof |
US7129359B2 (en) * | 2002-07-09 | 2006-10-31 | National Health Research Institutes | Imidazolidinone compounds |
US6706739B2 (en) * | 2001-08-21 | 2004-03-16 | National Health Research Institute | Imidazolidinone compounds |
CN100999441A (zh) * | 2006-01-13 | 2007-07-18 | 北京金源化学集团有限公司 | 红铝还原烷基丙二酸二酯为烷基-1,3-丙二醇 |
CA2687944A1 (en) * | 2007-05-24 | 2008-11-27 | Pfizer Limited | Spirocyclic quinazoline derivatives and their use as pde7 inhibitors |
TWI361808B (en) * | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
CN103351352B (zh) * | 2013-07-15 | 2015-10-21 | 南通市华峰化工有限责任公司 | 一种5-苯基四氮唑新合成方法 |
CN104744433B (zh) * | 2013-12-30 | 2016-09-21 | 中国科学院生物物理研究所 | Ald及其作为ev71病毒和cav16病毒抑制剂的用途 |
GB201402169D0 (en) * | 2014-02-07 | 2014-03-26 | Isis Innovation | Viral inhibitors |
WO2015165340A1 (zh) * | 2014-04-28 | 2015-11-05 | 南京明德新药研发股份有限公司 | 抗肠病毒71噻二唑烷衍生物 |
KR101957178B1 (ko) * | 2014-04-28 | 2019-03-12 | 지앙수 카니온 파마수티컬 씨오., 엘티디. | 항엔테로바이러스71 티아디아졸리딘 유도체 |
CN105085512A (zh) * | 2014-04-28 | 2015-11-25 | 南京明德新药研发股份有限公司 | 抗肠病毒71噻二唑烷衍生物 |
-
2016
- 2016-10-25 MY MYPI2017704188A patent/MY174415A/en unknown
- 2016-10-25 US US15/573,061 patent/US10227339B2/en active Active
- 2016-10-25 WO PCT/CN2016/103297 patent/WO2017071569A1/zh active Application Filing
- 2016-10-25 ES ES16859004T patent/ES2835061T3/es active Active
- 2016-10-25 CN CN201680011737.0A patent/CN107406439B/zh active Active
- 2016-10-25 EP EP16859004.0A patent/EP3257851B1/en active Active
- 2016-10-25 KR KR1020177029200A patent/KR102048391B1/ko active IP Right Grant
- 2016-10-25 DK DK16859004.0T patent/DK3257851T3/da active
- 2016-10-25 SG SG11201708692WA patent/SG11201708692WA/en unknown
- 2016-10-25 JP JP2017566189A patent/JP6427695B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
MY174415A (en) | 2020-04-17 |
KR102048391B1 (ko) | 2020-01-08 |
CN107406439B (zh) | 2020-06-16 |
DK3257851T3 (da) | 2020-12-14 |
EP3257851A4 (en) | 2018-09-19 |
US20180141940A1 (en) | 2018-05-24 |
KR20170124597A (ko) | 2017-11-10 |
EP3257851A1 (en) | 2017-12-20 |
ES2835061T3 (es) | 2021-06-21 |
JP6427695B2 (ja) | 2018-11-21 |
EP3257851B1 (en) | 2020-09-09 |
CN107406439A (zh) | 2017-11-28 |
WO2017071569A1 (zh) | 2017-05-04 |
JP2018509467A (ja) | 2018-04-05 |
US10227339B2 (en) | 2019-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3287444A4 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
HK1254055A1 (zh) | 製備奧貝膽酸及其衍生物的方法 | |
PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
GB201514760D0 (en) | Compounds and method of use | |
PL3398598T3 (pl) | Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie | |
HK1256860A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
EP3502103A4 (en) | CRYSTALLINE FORM, TYPE OF SALT OF A SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREOF | |
ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
ZA201902628B (en) | Non-solvated crystal, preparation method and application thereof | |
EP3239149A4 (en) | Crystal form i of canagliflozin and preparation method thereof | |
SI3327012T1 (sl) | Kristalinične oblike bilastina in postopki za pripravo le-teh | |
EP3272751A4 (en) | Crystal form of ipi-145 and preparation method thereof | |
IL254709A0 (en) | Methods for the use and production of innovative and useful salt for food | |
PL3330267T3 (pl) | Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu | |
EP3310377A4 (en) | Method of treating crohn's disease | |
EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
HK1258757A1 (zh) | 4H-吡唑並[1,5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體 | |
HK1252375A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
SG11201708692WA (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof | |
ZA201901120B (en) | Crystal and salt of nitroimidazole, and manufacturing method thereof | |
HK1232209A1 (zh) | 製備 -乙酰氧基丙酸及其衍生物的方法 | |
HK1226085A1 (zh) | 一種網紅細胞生長因子及其製備方法和應用 | |
PT3632909T (pt) | Sal e forma cristalina de composto de andrografólido modificado e seu método de preparação | |
ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound |